Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts - GlobeNewswire
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts GlobeNewswire
51% of subjects in Cohort 2 achieved complete clearance of all treatable warts. VP-102 was well-tolerated with no serious adverse events reported. Common ...
Comments
Post a Comment